Peter Tombros

Peter’s extensive experience addressing the unique challenges of biotech research will provide valuable insight to the Foundation’s mission to overcome the barriers that have limited progress in childhood cancer research.

FORT MYERS, Fla. (PRWEB)
June 22, 2020

Bridge To A Cure Foundation announced Peter Tombros, Executive Board Chair and Acting CEO of NeuExcell Therapeutics, as the newest member of its Board of Directors.

President and Board of Directors Chairman of Bridge To A Cure Foundation, Robert Martin, welcomed Tombros to the organization. “Peter’s extensive experience addressing the unique challenges of biotech research will provide valuable insight to the Foundation’s mission to overcome the barriers that have limited progress in childhood cancer research,” he explained. “His willingness to join us is testament of the unique approach Bridge To A Cure Foundation is taking to transform childhood cancer research.”

Tombros brings to Bridge To A Cure Foundation leadership in the pharmaceutical industry. His experience includes eight years as President and CEO of Enzon Pharma, where he grew the company into one of the top 20 biotech firms in the United States. Prior to that, Tombros spent over 25 years with Pfizer Inc. in a variety of senior executive positions. He currently serves an emeritus role as Professor and Distinguished Executive in Residence in the Eberly College of Sciences BS/MBA Program at the Pennsylvania State University. In 2015, he was selected “Financial Times 2015 Director of the Year.”

Prior to joining the Board of Directors at Bridge To A Cure Foundation, Tombros served on eight different publicly traded pharmaceutical company boards, and has been involved in a wide variety of board matters including CEO succession, corporate restructuring, financing, regulatory (FDA, SEC) dealings, and corporate governance issues.

About Bridge To A Cure Foundation

Bridge To A Cure Foundation, a 501(c)(3) charitable organization, raises funds to modernize childhood cancer research. Dedicated to healthier, happier kids, the organization’s action plan to accelerate the pace and success of childhood cancer research connects the people, information, and resources needed to propel life-saving cures. For more information, visit BridgeToACure.org.

Share article on social media or email:

Xtalks Life Science Webinars

Clearly, the world ‘post-COVID-19’ will be different from the world where we came from, but what impact can we expect, and what changes may last?

TORONTO (PRWEB)
June 22, 2020

With the emergence of SARS-CoV-2, we all have ‘lost our innocence’ by learning that an unexpected, novel infectious agent has a dramatic and, for today’s generations, unprecedented impact on lives, society, economy and as a consequence, on the domain of clinical drug development. Clearly, the world ‘post-COVID-19’ will be different from the world where we came from, but what impact can we expect, and what changes may last?

This webinar will start exploring clinical drug development in the setting of SARS-CoV-2 being a new entity to deal with, by addressing the questions:

• 
  What is known about SARS-CoV-2, its epidemiology and how it compares to earlier coronaviruses? What is known about COVID-19, the unexpected variation in its clinical presentation, in adults and in children, and the short- and long-term effects?
• How can active infection with SARS-CoV-2 be reliably measured and how can previous infection be proved by measuring immune response? How can we find our way in a myriad of tests that are becoming available in a rapid response setting, with limited, if any, regulatory oversight?
• Now that SARS-CoV-2 is amongst us, how should groups proceed with early clinical development programs, including first-in-human studies, whilst minimizing risk to study participants, maximizing informative value of the study and in compliance with all rules and regulations?
• COVID-19 has pressure tested clinical drug developers and regulators, and has brought about ad-hoc changes in regulatory approaches. What COVID-19 imposed regulatory changes can be expected to be long-lasting and here to stay?

Join Radboud van Trigt, PhD, Director of Bioanalytical Science – Biomarkers, PRA Health Sciences, Gregory P. Licholai, MD, MBA, Yale School of Management, Chief Medical Officer, PRA Health Sciences and Arwa Shurrab, Senior Director, Regulatory Strategy, PRA Health Sciences in a live webinar on Monday, July 13, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit The Impact of COVID-19 on Early Clinical Development – What the New Landscape Will Look Like.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Xtalks Life Science Webinars

This webinar will give an overview of each approach and discuss the types of questions that will help guide one to choose the correct technology.

TORONTO (PRWEB)
June 22, 2020

The field of quantitation of large molecules or proteins has been around for a long time. Typically, ligand binding assays (LBA) have dominated this area. However, the use of mass spectrometry in this field has gained a lot of momentum in the last several years.

This now necessitates the question “How do you choose which approach to use (LBA or MS)?” In many cases, either technology can answer the question, but there are definitely times when one technology has advantages over the other. There are several questions which might lead to specific direction, such as “what type of reagents are available?” or “do you need to differentiate a small amino acid change?”

This webinar will give an overview of each approach and discuss the types of questions that will help guide one to choose the correct technology. For the LBA, we will discuss the different types of ligand binding assays, answers to common questions that can lead to performing LBA vs. hybrid LCMS and some advantages of LBA over LCMS methodologies.

For Hybrid LCMS, we will discuss and highlight various approaches for using immunoaffinity LCMS or hybrid LCMS, from enrichment at the protein level to enrichment at the peptide level, using either bead-based or column-based enrichment strategies.

The presenters will also give examples and case studies of where each technology was applied successfully and where they had to pivot to an alternate technology.

Join Franklin Spriggs, MS Director, Biopharmaceutical LBA Services, KCAS Bioanalytical and Biomarker Services and Dawn Dufield, PhD, Director, Biopharmaceutical LC-MS/MS Services, KCAS Bioanalytical and Biomarker Services in a live webinar on Friday, July 10, 2020 at 12pm EDT (5pm BST/UK).

For more information or to register for this event, visit LBA and Hybrid LCMS Quantitation of Biotherapeutics and Biomarkers.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Altoros

SUNNYVALE, Calif. (PRWEB)
June 22, 2020

Altoros, a professional IT consultancy assisting Global 2000 organizations, today announced the launch of Temperature Screener, a product to help prevent the spread of COVID-19. Powered by artificial intelligence (AI), Temperature Screener identifies individuals with high body temperature—a major symptom of the SARS-CoV-2 virus.

Technology’s response to the pandemic

According to WHO, 87.9% of those infected with COVID-19 experience fever. As healthcare organizations across the world fight to control the outbreak, many public and private institutions are enacting preventive measures to minimize the spread of the coronavirus. In this situation, mass monitoring of body temperature becomes crucial.

While thermal cameras have existed for some time, they often lack tools for mass screening, as well as alerting, reporting, or storing the collected information. People wearing masks or other accessories also makes the process more difficult. Altoros’s Temperature Screener is a combination of a dual thermal camera with built in AI algorithms that smartly recognize human faces—even those covered with masks, glasses, or headwear.

“Healthcare workers are putting their lives at risk to treat and save patients, and we have a product that can help in minimizing the spread of the infection,” said Renat Khasanshyn, CEO at Altoros. “With Temperature Screener, we can quickly assess a large number of people to identify if someone has an elevated body temperature. Armed with that information, we assist health officials in ensuring that preventive measures are made quickly and properly, with the ultimate goal of reducing the burden on the medical staff.”

How Temperature Screener works

The product is capable of scanning up to 30 individuals simultaneously at a 3-meter distance with accuracy of ±0.3°С (±0.6°F). Temperature Screener supports recurrent temperature monitoring—i.e., diagnosing a potentially infected individual at specified time intervals.

Should a person with high temperature be identified, notifications—with attached photos, readings, and geolocation—are sent to specified recipients. If needed, custom triggers can be added, providing daily, weekly, and monthly reports across multiple parameters.

Temperature Screener is a fully automatic enterprise-grade product enabling organizations to set up temperature scanning checkpoints. The major components include:

●    a dual thermal / video camera

●    an AI module for temperature analysis

●    a customizable alerting / reporting system

●    a processing box with cloud data storage

●    web-based user management UI

“Temperature Screener is perfect for keeping essential industries (such as healthcare, retail, food, finance, and transportation) open and running, providing a building block to support proper safety,” added Khasanshyn.

What’s more?

In addition to thermal scanning, Altoros is working on enabling the system to detect other coronavirus symptoms, such as coughing, by analyzing the sound from sensors.

To schedule a demo, visit the Temperature Screener page:

https://www.altoros.com/solutions/mass-fever-screener-with-ai/

About Altoros

Altoros is a 300+ person strong consultancy that helps Global 2000 organizations with methodology, training, technology building blocks, and end-to-end solution development. The company turns cloud-native app development, customer analytics, blockchain, and AI into products with a sustainable competitive advantage. For more, visit http://www.altoros.com or follow @altoros.

# # #

Media contact:

Joanne Hogue

Smart Connections PR for Altoros

+1 (410) 658-8246

joanne@smartconnectionspr.com

Michael Jacobi

michael.j@altoros.com

+1 (650) 265-2266

Share article on social media or email:

Find lil’gourmets at select Meijer locations!

“We are excited to launch lil’gourmets veggie meals and look forward to adding their unique global recipes to our assortment.” – Meijer Buyer Matt Campbell

CHICAGO (PRWEB)
June 22, 2020

Expanding its reach across six states in the Midwest, lil’gourmets is delighted to announce that Michigan-based retailer, Meijer, will now be offering lil’gourmets veggie meals in retail locations as well as Meijer.com.

Founded by two former Kraft Food executives and first-time moms, lil’gourmets was created to cultivate curiosity in lil’ones by exposing them to nourishing, veggie-focused, global cuisines at a young age to help them fall in love with vegetables and diverse, culturally-rich foods for life. As the first and only fresh, organic veggie meal, lil’gourmets’ global recipes feature veggies and beans combined with nutritious ingredients like coconut milk and extra virgin olive oil with chef-crafted spice blends to create uniquely delicious homemade meals.

lil’gourmets and Meijer, creating a one-stop shop in the baby aisle

Shoppers will now be able to find lil’gourmets products in coolers located in the baby aisle, near other baby essentials, at select Meijer locations.

“Our investment in coolers in the baby aisle further enhances our commitment at Meijer to customer service by creating a complete and convenient assortment for families with young children,” Meijer Buyer Matt Campbell said. “We are excited to launch lil’gourmets veggie meals and look forward to adding their unique global recipes to our assortment.”

“We are thrilled to partner with Meijer as they roll out their consumer-centric approach to launching fresh food in the baby aisle,” says lil’gourmets CMO Becky Graham. “By offering the latest fresh food options next to other essentials, parents and caregivers can enjoy a one-stop shopping experience.”

Cultivating curiosity to nurture young eaters

“We started lil’gourmets because, as moms, we saw firsthand the connection between our kids’ first foods and their future eating habits,” says founder and CEO Shibani Baluja. “With our fresh, organic, global veggie meals, our mission is to help lil’ones fall in love with vegetables, while cultivating their curiosity for flavors and cultures from around the world. Through food, we can pique our children’s interest in and curiosity about a variety of cultures and help to make the world a smaller place!”

Responding to the demand from parents for a greater variety of vegetables and flavors, lil’gourmets now offers six delicious ways to cultivate a child’s curiosity: Cinnamon Beets & Apples, Coconut Cauliflower Mash, Moroccan Butternut Squash, Pumpkin Navy Bean Shawarma, Spanish Corn & Bean Gazpacho and Sweet Potato Curry.

About lil’gourmets

lil’gourmets is the first and only fresh organic veggie meal for kids. Created with a unique veggie-first promise, 100% of the lil’gourmets global recipes feature veggies and beans as the first and primary ingredients. With only 2-5g of sugar and uniquely delicious chef-crafted spice blends, these fresh, ready-to eat veggie meals are a perfect meal for a baby, a side dish for a toddler, or a healthy snack or dip for kids and adults of any age.

Winner of the NEXTY award for Best New Natural Kids Product, lil’gourmets products are refrigerated, certified organic, non-GMO, vegan, gluten-free, and cold-pressure processed. All 6 varieties are now available online and in select grocery and retail locations. For more announcements and up-to-date information about lil’gourmets, visit lilgourmets.com or follow them on Instagram.

About Meijer

Meijer is a Grand Rapids, Mich.-based retailer that operates more than 248 supercenters and grocery stores throughout Michigan, Ohio, Indiana, Illinois, Kentucky and Wisconsin. A privately-owned and family-operated company since 1934, Meijer pioneered the “one-stop shopping” concept and has evolved through the years to include expanded fresh produce and meat departments, as well as pharmacies, comprehensive apparel departments, pet departments, garden centers, toys and electronics. For additional information on Meijer, please visit http://www.meijer.com. Follow Meijer on Twitter @twitter.com/Meijer and @twitter.com/MeijerPR or become a fan at http://www.facebook.com/meijer.

Share article on social media or email:

Lincoln Equities Group has acquired a 1.2 million-square-foot pharmaceutical campus in Hopewell, N.J., formerly owned by global pharmaceutical company Bristol-Myers Squibb. (Image courtesy of BMS.)

“This spacious, modern BMS campus – located in the center of ‘Einstein’s Alley’ in Central New Jersey – is a prime location for continued innovation and expansion,” said LEG President Joel Bergstein.

HOPEWELL, N.J. (PRWEB)
June 22, 2020

Lincoln Equities Group (LEG), a full-service real estate firm, and H.I.G. Realty Partners, announced the acquisition of a 1.2 million-square-foot life sciences campus formerly owned by global biopharmaceutical company Bristol Myers Squibb. Brokerage firm JLL is marketing the 433-acre “Princeton West Innovation Campus,” located just 7 miles from Princeton, to life sciences companies. The secure, multipurpose research and development (R&D) and biologic/pharmaceutical manufacturing campus includes build-to-suit opportunities and is highly divisible into footprints of all sizes.

“Given the current public health crisis, we anticipate pharmaceutical and life sciences manufacturers to consider ‘reshoring’ and expanding operations in the U.S.,” said Joel Bergstein, president of LEG. “This spacious, modern BMS campus – located in the center of ‘Einstein’s Alley’ in Central New Jersey – is a prime location for continued innovation and expansion.”

The BMS campus is located along the Boston – Washington, D.C. life sciences corridor in central New Jersey’s research technology region – home to emerging and established Fortune 500 life sciences companies. Current tenants include PTC Therapeutics Inc., which occupies over 200,000 square feet, including a biologics production facility and R&D buildings.

The site is also zoned for commercial manufacturing and features 35 acres of additional development opportunity; it can expand to approximately 2.8 million square feet. The development parcel offers Class-A infrastructure with fully stubbed utilities allowing for a compressed development timeline.

“This campus presents an opportunity to capitalize on the growing demand for pharmaceutical-grade lab space both locally and nationally,” said Ira Weidhorn, Co-Head of H.I.G. Realty Partners. “We look forward to building around the strong in-place anchor tenancy of PTC and leveraging H.I.G.’s real estate expertise and bio-health experience to enhance the execution of the value-add business plan.”

The Princeton West Innovation Campus features nine principal buildings consisting of state-of-the-art clinical manufacturing, plug-and-play biological laboratories and office space, plus freestanding R&D support space, storage facilities and a global data and command center.

It is supported by a central utility complex (CUC), which provides wastewater management, generator-backed electricity, chilled water and steam. Onsite amenities include a full-service cafeteria, an 8,000-square-foot fitness center and a freestanding, 28,000-square-foot child development center; plus, multiple conference areas, including a 9,000-square-foot mansion, the campus’ original building. The site is just minutes from downtown Princeton, I-95, I-295 and Routes 1, 31, 206 and within 12 miles of three Amtrak train stations.

LEG will manage the property through its Life Sciences division, a team dedicated to expanding and managing the company’s life sciences portfolio.

“Our Life Sciences division at LEG has grown to nearly 2 million square feet with the addition of the former BMS campus,” said Lance Bergstein, acquisitions and development officer at LEG. “New Jersey has one of the most highly educated and skilled workforces in the U.S., including the highest concentration of scientists and engineers in the world. Our Life Sciences team expects to see an influx of investment across the state.”

About Lincoln Equities Group

Lincoln Equities Group LLC (LEG), established in 1980, is one of the Northeast’s leading full‐service real estate companies. The company owns, operates, develops and manages commercial, industrial and residential properties throughout the tri‐state area and Europe, for its own account and for third‐party owners. http://www.lincolnequities.com.

About H.I.G. Realty Partners

H.I.G. Realty Partners is the real estate platform of H.I.G. Capital, a leading global private equity and alternative assets investment firm with $37 billion of equity capital under management, and manages $2.6 billion in capital commitments focused on small-to-mid cap real estate assets. H.I.G. Realty Partners targets both equity and debt investments across all property types located throughout the U.S. and Europe. Equity investments are concentrated on the acquisition of value-add assets, employing a hands-on, operationally focused approach that seeks to generate substantial cash flow and asset appreciation through rehabilitating, redeveloping, repositioning and rebranding assets. Debt investments include senior bridge loans, mezzanine loans and preferred equity collateralized by transitional properties and portfolios. For more information, please refer to the H.I.G. website http://www.higcapital.com.

Share article on social media or email:

Amniotic Derived Exosomes – Amniosomes now buy 3 get one free (888) 568-6909

Amniosomes represents the most pure exosome product in the country. Feedback from our customers has been stellar, so we wanted to offer a special during the summer months!

SCOTTSDALE, Ariz. (PRWEB)
June 22, 2020

Regen Suppliers, the one stop shop for regenerative products, is now offering an Amniosomes special offer. This includes buy three, get the fourth unit free with no limit on the amniotic derived exosomes. Interested providers should call (888) 568-6909.

Amniotic derived exosomes, known as exosomes, have been a game changer for regenerative therapies. The products are manufactured at an FDA Certified lab that is cGMP compliant.

Sourced from “Single Birth” placental donors, potent amnio-derived extracellular vesicles are suspended in clarified amniotic fluid. The products are cryopreserved until being thawed out just before use.

This preserves the full spectrum functional miRNA, RNA, peptides, and growth factors that support fetal development. Particulate debris are carefully filtered out for the most pure extracellular vesicle product available today.

According to Regen Suppliers CEO David Greene, “Amniosomes represents the most pure exosome product in the country. Feedback from our customers has been stellar, so we wanted to offer a special during the summer months!”

There is no limit on the current special, which runs through August 31, 2020. In addition to the amniotic derived exosome offer, Regen Suppliers is also offering a new Rewards Program, where customers receive points towards free products and training. Just for signing up as a member on https://regensuppliers.com, providers receive 1000 points.

As a top exosome supplier, Regen Suppliers offers a freezer program and comprehensive stem cell and exosome training as well. Call (888) 568-6909 for more information.

Share article on social media or email: